LONGEVA.

SLU-PP-915: limits of adverse-event evidence

Billon and colleagues studied SLU-PP-915 in mice using oral and intraperitoneal administration. The inspected abstract describes endurance and molecular measurements, rather than clinical adverse-event frequencies. [1]

This abstract cannot establish adverse reactions or safety in humans or for a particular reagent batch. Findings about SLU-PP-332 should not automatically be transferred to the distinct SLU-PP-915 molecule. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Clinical adverse-event frequenciesMice, oral and intraperitoneal administrationThe abstract describes endurance and molecular measurements rather than clinical adverse-event frequencies; findings about SLU-PP-332 do not transfer to this distinct molecule[1]

References

  1. Billon C et al. (2026). An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity https://doi.org/10.1016/j.jpet.2025.103787.